On March 6, 2026, at roughly 2:00 PM Eastern, the single largest research peptide vendor in the United States went dark. Visitors to peptidesciences.com were met with a short, red-bordered notice on an otherwise blank page: the company had "voluntarily" decided to shut down operations and discontinue the sale of all research products. There was no advance warning, no guidance for customers with pending orders, and no explanation beyond that one word.
For a company that had operated for over a decade, drew an estimated 990,000 monthly visits, and reportedly generated around $7.4 million in sales in December 2025 alone, the abruptness stunned the research community. If a vendor this established could disappear overnight, the thinking went, no grey-market supplier is safe.
Here is a complete, plain-English breakdown of what happened, the regulatory and quality forces behind the closure, and what it signals for the future of peptide access in 2026.
Key Takeaways
- Peptide Sciences voluntarily shut down on March 6, 2026, posting a brief farewell notice and going offline the same day.
- The closure was "voluntary" but not random. Industry analysts attribute it to converging pressure: escalating FDA and DOJ enforcement, independent testing that exposed quality failures, and the collapse of the high-margin GLP-1 revenue stream.
- There is no refund process and no customer support. If you had a pending order or store credit, a credit-card chargeback is your most realistic recourse.
- Any site still selling under the Peptide Sciences name is fraudulent. The company has not authorized a successor, and independent testing platforms have warned buyers directly.
- The timing is ironic: just weeks earlier, federal officials signaled that several restricted peptides may return to legal compounding, a shift that further undermines the grey-market model.
What Happened: The Peptide Sciences Shutdown
Peptide Sciences was, by web traffic and estimated revenue, the dominant name in the US "research use only" peptide market. Based in Henderson, Nevada, it sold dozens of compounds, including BPC-157, TB-500, retatrutide, semaglutide, and tirzepatide, all labeled strictly for laboratory research and not for human use.
That scale is exactly what made the shutdown so jarring. The notice that replaced its homepage read, in part:
"After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products. We are deeply grateful for your trust and support. Thank you for being part of the Peptide Sciences community."
No forwarding address. No timeline for refunds. No statement about what happens to customer data or outstanding inventory. Within hours, customer-support channels stopped responding, and peptide forums and subreddits filled with confused customers trying every available contact method.
